JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis



Status:Recruiting
Conditions:Psoriasis, Dermatology, Dermatology, Dermatology
Therapuetic Areas:Dermatology / Plastic Surgery
Healthy:No
Age Range:12 - 17
Updated:3/27/2019
Start Date:February 18, 2019
End Date:January 23, 2020
Contact:Pfizer CT.gov Call Center
Email:ClinicalTrials.gov_Inquiries@pfizer.com
Phone:1-800-718-1021

Use our guide to learn which trials are right for you!

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842 CO-ADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS

This is a randomized, double blind, placebo controlled, parallel group, Phase 3 study to
evaluate the efficacy and safety of PF 04965842 in adolescent participants 12 to <18 years of
age with moderate to severe AD.

This is a randomized, double blind, placebo controlled, parallel group, Phase 3 study to
evaluate the efficacy and safety of PF 04965842 in adolescent participants 12 to <18 years of
age with moderate to severe AD. Participants will be screened within 28 days prior to the
first dose of study intervention to confirm study eligibility. Subjects must have
moderate-severe AD involving at least 10% Body Surface Area (BSA); an Investigator Global
Assessment (IGA) score of at least 3; an Eczema Area Severity Index (EASI) of at least 16 and
Peak Pruritus Numerical Rating Score (NRS) of at least 4 on baseline/Day 1. Eligible subjects
will be randomized at the Baseline/Day 1 visit. Approximately 225 participants will be
randomized in a 1:1:1 ratio to receive once daily PF 04965842 at 200 mg, 100 mg, or placebo
for 12 weeks. Randomization will be stratified by baseline disease severity (moderate [IGA =
3] vs. severe [IGA = 4] AD). The investigational products will be administered QD for 12
weeks. Background therapy (medicated and non-medicated topical therapy) must be applied BID
for the duration of the treatment period. The co-primary efficacy endpoints are an IGA score
of clear (0) or almost clear (1) with a reduction from baseline of greater than 2 points at
Week 12 AND an at least 75% improvement of the EASI score (EASI-75) at week 12. Safety and
efficacy assessments will be conducted at the investigator site by a clinical assessor
blinded to treatment assignment. Scheduled clinic or telephone study visits for all subjects
will occur at Screening, Baseline/Day 1, Day 8 (by phone), Day 15, Day 29, Day 43 (by phone),
Day 57, Day 85 (End of treatment/Early termination), Day 113 (End of Study). Participants
discontinuing early from the study will undergo a 4 week follow up period.

This study includes an immunogenicity sub study integrated into the last 4 weeks of the main
study treatment period. At Week 8, up to approximately 90 participants (up to approximately
30 in each treatment arm) who have completed 8 weeks of treatment with study intervention
will receive a tetanus, diphtheria and acellular pertussis combination vaccine (Tdap), and
collection of blood samples for the evaluation of immunogenicity at Weeks 8 and 12.
Participants of this sub study will complete all other protocol specified procedures in the
main study.

At the end of the 12 week study treatment, qualified participants completing the study will
have the option to enter the long term extension (LTE) study B7451015.

Inclusion Criteria:

- Aged between 12 and to 17 with a minimum body weight of 40 kg

- Diagnosis of atopic dermatitis (AD) for at least 1 year and current status of moderate
to severe disease (>= the following scores: BSA 10%, IGA 3, EASI 16, Pruritus NRS
severity 4)

Exclusion Criteria:

- Acute or chronic medical or laboratory abnormality that may increase the risk
associated with study participation

- Unwilling to discontinue current AD medications prior to the study or require
treatment with prohibited medications during the study

- Prior treatment with JAK inhibitors

- Other active non-AD inflammatory skin diseases or conditions affecting skin

- Medical history including thrombocytopenia, coagulopathy or platelet dysfunction,
malignancies, current or history of certain infections, lymphoproliferative disorders
and other medical conditions at the discretion of the investigator

- Pregnant or breastfeeding women, or women of childbearing potential who are unwilling
to use contraception
We found this trial at
23
sites
Clarkston, Michigan 48346
?
mi
from
Clarkston, MI
Click here to add this to my saved trials
?
mi
from
Austin, TX
Click here to add this to my saved trials
?
mi
from
Boise, ID
Click here to add this to my saved trials
Cincinnati, Ohio 42536
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Columbus, Georgia 31904
?
mi
from
Columbus, GA
Click here to add this to my saved trials
?
mi
from
Coral Gables, FL
Click here to add this to my saved trials
Fremont, California 94538
?
mi
from
Fremont, CA
Click here to add this to my saved trials
?
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Indianapolis, Indiana 46256
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
2919 West Swann Avenue
Largo, Florida 33770
?
mi
from
Largo, FL
Click here to add this to my saved trials
Las Vegas, Nevada 89119
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Louisville, Kentucky 40202
?
mi
from
Louisville, KY
Click here to add this to my saved trials
Miami, Florida 33184
?
mi
from
Miami, FL
Click here to add this to my saved trials
?
mi
from
Mission Viejo, CA
Click here to add this to my saved trials
Neyagawa, Osaka 57208
?
mi
from
Neyagawa,
Click here to add this to my saved trials
Norfolk, Virginia 23507
?
mi
from
Norfolk, VA
Click here to add this to my saved trials
2010 Jacobssen Drive
Normal, Illinois 61761
?
mi
from
Normal, IL
Click here to add this to my saved trials
Orlando, Florida 32801
?
mi
from
Orlando, FL
Click here to add this to my saved trials
Rockville, Maryland 20850
?
mi
from
Rockville, MD
Click here to add this to my saved trials
Santa Rosa, California 95405
?
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
Savannah, Georgia 31406
?
mi
from
Savannah, GA
Click here to add this to my saved trials
Tampa, Florida 33613
?
mi
from
Tampa, FL
Click here to add this to my saved trials
?
mi
from
Webster, TX
Click here to add this to my saved trials